Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biotechnology company Amgen has entered into partnership with Servier, a French research-based pharmaceutical company, to bring potential new cardiovascular treatment options to patients in both the US and Europe.
Subscribe to our email newsletter
Under the partnership, Amgen has received commercial rights in the US to Servier’s novel oral drug, which was approved in the EU as Procoralan (ivabradine) for chronic heart failure and stable angina in patients with increased heart rates.
Servier CEO Dr Jean-Philippe Seta said, "This is a clear recognition of the medical value of ivabradine, one of our major cardiovascular innovations, which could also benefit U.S. patients."
Amgen has also obtained an exclusive option to develop and commercialize Servier’s investigational molecule, S38844, for cardiovascular diseases in the US.
Servier has obtained rights in Europe to commercialize omecamtiv mecarbil, an activator of cardiac myosin, which is used in the treatment of heart failure in patients with systolic dysfunction.
Financial terms of Amgen’s option for S38844 and Servier’s option for omecamtiv mecarbil were not disclosed.
As per the agreement, Amgen will make a one-time $50m upfront payment and future milestone and royalty payments for ivabradine.
Servier Research and Development head Dr Emmanuel Canet added, "The clinical benefit and safety profile are supported by the results of clinical studies performed or being performed in more than 40,000 patients."